Patents by Inventor Derek O'Hagan

Derek O'Hagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11291635
    Abstract: Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: April 5, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICAL SA
    Inventors: Andrew Geall, Christian Mandi, Derek O'Hagan, Manmohan Singh
  • Publication number: 20220080043
    Abstract: Methods of manufacturing squalene and alpha-tocopherol-containing oil-in-water emulsions having small oil droplet particle sizes. Such emulsions being of use as vaccine adjuvants.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 17, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Rushit LODAYA, Mansoor AMIJI, Derek O'HAGAN
  • Patent number: 11246921
    Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: February 15, 2022
    Assignee: Seqirus UK Limited
    Inventors: Mario Contorni, Derek O'Hagan, Nicola Groth
  • Patent number: 11197826
    Abstract: Retinoic acid, or an analogue thereof, is delivered within an oil-in-water emulsion to provide an improved immunological adjuvant.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 14, 2021
    Assignee: NOVARTIS AG
    Inventors: Ugo D'Oro, Luis Brito, Derek O'Hagan, Silvia Vendetti
  • Patent number: 11167028
    Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: November 9, 2021
    Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan
  • Patent number: 11135287
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: October 5, 2021
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Luis Brito, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Publication number: 20210170021
    Abstract: An immunogenic composition comprising: (i) a non-virion influenza virus antigen, prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 10, 2021
    Inventors: Rino RAPPUOLI, Derek O'Hagan, Giuseppe DEL GIUDICE
  • Patent number: 11026890
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: June 8, 2021
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Luis Brito, Michelle C. Archer, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Patent number: 10842867
    Abstract: An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: November 24, 2020
    Assignee: Seqirus UK Limited
    Inventors: Rino Rappuoli, Derek O'Hagan, Giuseppe Del Giudice
  • Patent number: 10842868
    Abstract: The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: November 24, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Barbara Baudner, Derek O'Hagan, Manmohan Singh, Simone Bufali
  • Publication number: 20200155664
    Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
    Type: Application
    Filed: June 26, 2019
    Publication date: May 21, 2020
    Inventors: Mario CONTORNI, Derek O'HAGAN, Nicola GROTH
  • Patent number: 10603369
    Abstract: Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 31, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Barbara Baudner, David Skibinski, Manmohan Singh, Derek O'Hagan
  • Patent number: 10485761
    Abstract: In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: November 26, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Padma Malyala
  • Publication number: 20190262448
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.
    Type: Application
    Filed: March 7, 2019
    Publication date: August 29, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Luis BRITO, Andrew GEALL, Derek O'HAGAN, Manmohan SINGH
  • Publication number: 20190254968
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.
    Type: Application
    Filed: May 2, 2019
    Publication date: August 22, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis BRITO, Michelle C. ARCHER, Andrew GEALL, Derek O'HAGAN, Manmohan SINGH
  • Patent number: 10357568
    Abstract: To formulate amphiphilic pharmacological agents (in particular, amphiphilic immunopotentiators) in oil-in-water emulsions the invention provides an oil-in-water emulsion comprising an aqueous phase, an oil phase, a surfactant, and a phospholipid.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: July 23, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Manmohan Singh, Derek O'Hagan
  • Publication number: 20190167786
    Abstract: A split influenza virus vaccine is adjuvanted with an oil-in-water emulsion that contains free surfactant in its aqueous phase. The free surfactant can continue to exert a ‘splitting effect’ on the antigen, thereby disrupting any unsplit virions and/or virion aggregates that might be present.
    Type: Application
    Filed: July 9, 2018
    Publication date: June 6, 2019
    Inventor: Derek O'Hagan
  • Patent number: 10307374
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: June 4, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Michelle C. Archer, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Patent number: 10286056
    Abstract: High loading of lipophilic pharmacological agents (in particular, lipophilic immunopotentiators) in oil-in-water emulsions can result in crystallisation of the lipophilic agent. To overcome this problem the invention uses an oil-in-water emulsion in combination with a crystallisation inhibitor, and this combination provides emulsions which can be loaded with high levels of lipophilic pharmacological agents.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: May 14, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Luis Brito, Manmohan Singh, Derek O'Hagan
  • Publication number: 20190091329
    Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.
    Type: Application
    Filed: December 6, 2018
    Publication date: March 28, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan